Fasenra vs Tezspire
A side-by-side look at two respiratory medications advertised on TV. Informational only — not medical advice.
| US Fasenra | US Tezspire | |
|---|---|---|
| Generic name | benralizumab | tezepelumab |
| Drug class | IL-5 Receptor Antagonist (Biologic) | TSLP Blocker (Biologic) |
| Treats | Severe eosinophilic asthma | Severe asthma |
| Category | Respiratory | Respiratory |
| Manufacturer | AstraZeneca | Amgen/AstraZeneca |
| Year approved | 2017 | 2021 |
| FDA warning | No boxed warning | No boxed warning |
| Est. TV ad spend | $80M | $70M |
| Common side effects | Headache, Sore throat, Allergic reactions, Injection site reactions | Sore throat, Joint pain, Back pain, Injection site reactions |
Frequently asked questions
Is Fasenra or Tezspire better?
Neither is universally "better." Fasenra (benralizumab) and Tezspire (tezepelumab) are both used for respiratory, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Fasenra and Tezspire?
Fasenra is a IL-5 Receptor Antagonist (Biologic) made by AstraZeneca, while Tezspire is a TSLP Blocker (Biologic) made by Amgen/AstraZeneca. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Fasenra has the larger estimated TV advertising budget of the two.